

Erratum

Akiko Nagata, Makoto Nasu, Yusuke Kaida, Yosuke Nakayama, Yuka Kurokawa, Nao Nakamura, Ryo Shibata, Takuma Hazama, Takahiro Tsukimura, Tadayasu Togawa, Seiji Saito, Hitoshi Sakuraba and Kei Fukami

Screening of Fabry disease in patients with chronic kidney disease in Japan, *Nephrol Dial Transplant* 2021; gfaa324. doi: 10.1093/ndt/gfaa324

In the original publication of this article, the coloured text in [Table 3](#) and [Table 4](#) was missing. These Tables should appear as:

Table 3. Summary of the recent screening for FD in male patients with CKD Stage 5D

No.	Authors	Country	Date of publication	No. of total male patients	Screening method of α -Gal A activity	Gene mutations (No. of patients) Red: Classic Blue: Late-onset Green: Unknown Black: Functional variants	Prevalence of FD without functional variants (%)
1	Utsumi K <i>et al.</i> [20]	Japan	2000	440	Plasma	p. Gln357Xaa (1) N/A (1)	2/440 (0.45)
2	Nakao S <i>et al.</i> [21]	Japan	2003	514	Plasma	p. Gly373Asp (1) p. Met296Ile (3) p. Ala97Val (1) p. Glu66Gln (1)	5/514 (0.97)
3	Linhorst GE <i>et al.</i> [22]	Netherlands	2003	508	Whole blood	p. D299E (1)	1/508 (0.20)
4	Kotanko P <i>et al.</i> [23]	Austria	2004	1,516	DBS test	p. Ala121Pro (1) p. Trp162Arg (1) p. Ile239Thr (1) p. Arg112His (1)	4/1,516 (0.26)
5	Ichinose M <i>et al.</i> [24]	Japan	2005	450	Plasma	c.761_763delTTG (1)	1/450 (0.22)
6	Tanaka M <i>et al.</i> [25]	Japan	2005	401	Plasma	p. Tyr365Xaa (2) 288AAT-AT(DelA) (1) ^a p. Met296Ile (1)	4/401 (1.00)
7	Bekri S <i>et al.</i> [5]	France	2005	59	Blood leukocytes	p. Asn215Ser (1)	1/59 (1.69)
8	Merta M <i>et al.</i> [26]	Czech Republic	2007	1,521	DBS test	p. Gly360Ser (1) p. Ile317Thr (1) p. Arg112His (1) p. Ala143Thr (1)	3/1,521 (0.20)
9	Porsch DB <i>et al.</i> [27]	Brazil	2008	558	DBS test	N/A (1) N/A (1)	2/558 (0.36)
10	Terryn W <i>et al.</i> [28]	Belgium	2008	180	DBS test	p. Trp236Arg (1)	1/180 (0.56)
11	Andrade J <i>et al.</i> [4]	Canada	2008	499	Plasma	N/A (0)	0/499 (0)
12	Fujii H <i>et al.</i> [29]	Japan	2009	635	DBS test	p. Glu66Gln (1)	0/635 (0)
13	Gaspar P <i>et al.</i> [30]	Spain	2010	543	DBS test	c.1037delG (1) p. Asp313Thr (1) p. Arg118Cys (2)	1/543 (0.19)
14	Wallin EF <i>et al.</i> [31]	UK	2011	155	DBS test	N/A (0)	0/155 (0)
15	Nishino T <i>et al.</i> [32]	Japan	2012	557	DBS test	p. Glu66Gln (1)	0/557 (0)
16	Kalkan Uçar S <i>et al.</i> [33]	Turkey	2012	808	Plasma	c.335>t (1) ^a p. Ala143Tyr (1)	1/808 (0.12)
17	Okur I <i>et al.</i> [34]	Turkey	2013	615	DBS test	p. Pro214Ser (1)	2/615 (0.33)

Table 3. (continued)

No.	Authors	Country	Date of publication	No. of total male patients	Screening method of α -Gal A activity	Gene mutations (No. of patients) Red: Classic Blue: Late-onset Green: Unknown Black: Functional variants	Prevalence of FD without functional variants (%)
18	Doi K <i>et al.</i> [11]	Japan	2013	1,080	Plasma	p.Leu275Phe (1) p.Gly195Val (1) p.Met296Ile (1) p.Glu66Gln (8)	2/1,080 (0.19)
19	Maruyama H <i>et al.</i> [35]	Japan	2013	1,453	Plasma	p.Yyr173Xaa (1) p.Glu66Gln (7)	1/1,453 (0.07)
20	Herrera J <i>et al.</i> [36]	Spain	2014	2,239	DBS test	c.1037delG (1) p.Asp109Gly (1) p.Arg118Cys (2)	2/2,239 (0.09)
21	Sayilar EI <i>et al.</i> [37]	Turkey	2016	847	DBS test	c.1212_1214delAAG (1) p.Met296Val (1) p.Arg112His (1) p.Ser65Asn (1) p.Asp313Tyr (1)	4/847 (0.47)
22	Saito O <i>et al.</i> [38]	Japan	2016	5,408	Plasma	p.Arg112Cys (2) p.Glu66Gln (7)	2/5,408 (0.04)
23	Silva CA <i>et al.</i> [39]	Salvador	2016	2,583	DBS test	p.Trp204Xaa (1) p.Ala368Thr (1) p.Cys52Phe (1)	3/2,583 (0.12)
24	Veloso VSP <i>et al.</i> [40]	Brazil	2018	108	DBS test	p.Gly35Val (1)	1/108 (0.93)
25	Moiseev S <i>et al.</i> [41]	Russian Federation	2019	3,551	DBS test	p.Trp262Xaa (1) p.Arg220Xaa (1) p.Arg342Gln (1) p.Trp399Xaa (1) p.Arg227Xaa (1) p.Cys56Ser (1) p.Gly183Ser (1) p.Gly328Arg (1) p.Tyr134Asp (1) p.Trp204Cys (1) p.Asp170Tyr (1) p.Glu7Xaa (1) p.Glu273Ser (1) p.Leu54Pro (3) p.Leu68Pro (1) p.Asn215Ser (1) p.Ala37Ser (1) p.Met208Arg (1) N/A (2) p.Glu66Gln (7)	19/3,551 (0.54)
26	Nagata A <i>et al.</i> [42]	Japan	2020	1,703	Serum	p.Met208Arg (1) N/A (2) p.Glu66Gln (7)	1/1,703 (0.06)
Total				28,931		No. of patients: total 105 Classic type (%): 42 (40.0) Late-onset type (%): 18 (17.1) Unknown (%): 3 (2.9) Functional variants (%): 42 (40.0)	63/28,931 (0.22)

^aThese descriptions were in line with the originally published data. However, in these *GLA* gene variants: 1) the 288AAT-AT (*DelA*) in No. 6 does not match the *GLA* cDNA sequence, and 2) the *c.335>t* in No. 16 might be wrongly described.
DBS, dried blood spot; NA, not applicable.

Table 4. Summary of the recent screening for FD in male patients with CKD Stages 1-5

No.	Authors	Country	Date of publication	No. of total male patients	Screening method of α -Gal A activity	Gene mutations (No. of patients) Red: Classic Blue: Late-onset Black: Functional variants	Prevalence of FD without functional variants (%)
1	Turkmen K <i>et al.</i> [7]	Turkey	2016	167	Plasma	p.Asn34His (1) c.1072_1074delGAG (1) p.Phe229Val (1)	3/167 (1.80)
2	Lin CJ <i>et al.</i> [8]	Taiwan	2018	1,012	DBS test	p.Thr410Ala (1) p.Gly138Glu (1) c.639 + 919G>A (3) p.Pro210Ser (1)	6/1,012 (0.59)
3	Nagata A <i>et al.</i> [42]	Japan	2020	419	Serum	c.370delG (1) p.Met296Ile (1) p.Glu66Gln (1) N/A (1)	2/419 (0.48)
Total				1,601		No. of patients as FD: total 13 Classic type (%): 5 (38.5) Late-onset type (%): 6 (46.2) Functional variants (%): 2 (15.3)	11/1,598 (0.69)

NA, not applicable.

The coloured text is now corrected within [Table 3](#) and [Table 4](#) in the article.

Table 3. Summary of the recent screening for FD in male patients with CKD Stage 5D

No.	References	Country	Date of publication	Male patients, <i>n</i>	Screening method of α -Gal A activity	Gene mutations (no. of patients) Red: Classic Blue: Late-onset Green: Unknown Black: Functional variants	Prevalence of FD without functional variants, <i>n/N</i> (%)
1	Utsumi <i>et al.</i> [20]	Japan	2000	440	Plasma	p. Gln357Xaa (1) NA (1)	2/440 (0.45)
2	Nakao <i>et al.</i> [21]	Japan	2003	514	Plasma	p.Gly373Asp (1) p.Met296Ile (3) p. Ala97Val (1) p.Glu66Gln (1)	5/514 (0.97)
3	Linthorst <i>et al.</i> [22]	Netherlands	2003	508	Whole blood	p.D299E (1)	1/508 (0.20)
4	Kotanko <i>et al.</i> [23]	Austria	2004	1516	DBS test	p.Ala121Pro (1) p.Trp162Arg (1) p. Ile239Thr (1) p.Arg112His (1)	4/1516 (0.26)
5	Ichinose <i>et al.</i> [24]	Japan	2005	450	Plasma	c.761_763delTTG (1)	1/450 (0.22)
6	Tanaka <i>et al.</i> [25]	Japan	2005	401	Plasma	p.Tyr365Xaa (2) 288AAT-AT(DelA) (1)^a	4/401 (1.00)
7	Bekri <i>et al.</i> [5]	France	2005	59	Blood leukocytes	p.Met296Ile (1) p.Asn215Ser (1)	1/59 (1.69)
8	Merta <i>et al.</i> [26]	Czech Republic	2007	1521	DBS test	p.Gly360Ser (1)p.Ile317Thr (1)p.Arg112His (1) p.Ala143Thr (1)	3/1521 (0.20)
9	Porsch <i>et al.</i> [27]	Brazil	2008	558	DBS test	NA (1) NA (1)	2/558 (0.36)
10	Terryin <i>et al.</i> [28]	Belgium	2008	180	DBS test	p.Trp236Arg (1)	1/180 (0.56)
11	Andrade <i>et al.</i> [4]	Canada	2008	499	Plasma	NA (0)	0/499 (0)
12	Fujii <i>et al.</i> [29]	Japan	2009	635	DBS test	p.Glu66Gln (1)	0/635 (0)
13	Gaspar <i>et al.</i> [30]	Spain	2010	543	DBS test	c.1037delG (1) p.Asp313Thr (1) p. Arg118Cys (2)	1/543 (0.19)
14	Wallin <i>et al.</i> [31]	UK	2011	155	DBS test	NA (0)	0/155 (0)

Table 3. (continued)

No.	References	Country	Date of publication	Male patients, <i>n</i>	Screening method of α -Gal A activity	Gene mutations (no. of patients) Red: Classic Blue: Late-onset Green: Unknown Black: Functional variants	Prevalence of FD without functional variants, <i>n/N</i> (%)
15	Nishino <i>et al.</i> [32]	Japan	2012	557	DBS test	p.Glu66Gln (1)	0/557 (0)
16	Kalkan Uçar <i>et al.</i> [33]	Turkey	2012	808	Plasma	c.335>t (1)^a p.Ala143Tyr (1)	1/808 (0.12)
17	Okur <i>et al.</i> [34]	Turkey	2013	615	DBS test	p.Pro214Ser (1) p.Leu275Phe (1)	2/615 (0.33)
18	Doi <i>et al.</i> [11]	Japan	2013	1080	Plasma	p.Gly195Val (1) p.Met296Ile (1) p.Glu66Gln (8)	2/1080 (0.19)
19	Maruyama <i>et al.</i> [35]	Japan	2013	1453	Plasma	p.Yyr173Xaa (1) p.Glu66Gln (7)	1/1453 (0.07)
20	Herrera and Miranda [36]	Spain	2014	2239	DBS test	c.1037delG (1) p.Asp109Gly (1) p. Arg118Cys (2)	2/2239 (0.09)
21	Sayilar <i>et al.</i> [37]	Turkey	2016	847	DBS test	c.1212_1214delAAG (1) p.Met296Val (1) p. Arg112His (1) p.Ser65Asn (1) p. Asp313Tyr (1)	4/847 (0.47)
22	Saito <i>et al.</i> [38]	Japan	2016	5408	Plasma	p.Arg112Cys (2) p.Glu66Gln (7)	2/5408 (0.04)
23	Silva <i>et al.</i> [39]	Salvador	2016	2583	DBS test	p.Trp204Xaa (1) p.Ala368Thr (1) p. Cys52Phe (1)	3/2583 (0.12)
24	Veloso <i>et al.</i> [40]	Brazil	2018	108	DBS test	p.Gly35Val (1)	1/108 (0.93)
25	Moiseev <i>et al.</i> [41]	Russian Federation	2019	3551	DBS test	p.Trp262Xaa (1) p.Arg220Xaa (1) p. Arg342Gln (1) p.Trp399Xaa (1) p. Arg227Xaa (1) p.Cys56Ser (1) p. Gly183Ser (1) p.Gly328Arg (1) p. Tyr134Asp (1) p.Trp204Cys (1) p. Asp170Tyr (1) p.Glu7Xaa (1) p. Glu273Ser (1) p.Leu54Pro (3)p.Leu68Pro (1) p.Asn215Ser (1) p. Ala37Ser (1)	19/3551 (0.54)
26	Nagata <i>et al.</i> [42]	Japan	2020	1703	Serum	p.Met208Arg (1) NA (2) p.Glu66Gln (7)	1/1703 (0.06)
Total				28 931		No. of patients: 105 Classic type, <i>n</i> (%): 42 (40.0) Late-onset type, <i>n</i> (%): 18 (17.1) Unknown, <i>n</i> (%): 3 (2.9) Functional variants, <i>n</i> (%): 42 (40.0)	63/28 931 (0.22)

^aThese descriptions were in line with the originally published data, however, the 288AAT-AT (DeLA) in no. 6 does not match the *GLA* cDNA sequence and the c.335>t in no. 16 might be wrongly described.

DBS, dried blood spot; NA, not applicable.

Table 4. Summary of the recent screening for FD in male patients with CKD Stages 1–5

No.	References	Country	Date of publication	Male patients, <i>n</i>	Screening method of α -Gal A activity	Gene mutations (no. of patients) Red: Classic Blue: Late-onset Black: Functional variants	Prevalence of FD without functional variants (%)
1	Turkmen <i>et al.</i> [7]	Turkey	2016	167	Plasma	p.Asn34His (1) c.1072_1074delGAG (1) p. Phe229Val (1)	3/167 (1.80)
2	Lin <i>et al.</i> [8]	Taiwan	2018	1012	DBS test	p.Thr410Ala (1) p.Gly138Glu (1) c.639 + 919G>A (3) p.Pro210Ser (1) c.370delG (1) p.Met296Ile (1) p. Glu66Gln (1) NA (1)	6/1012 (0.59)
3	Nagata <i>et al.</i> [42]	Japan	2020	419	Serum	p.Pro210Ser (1) c.370delG (1) p.Met296Ile (1) p. Glu66Gln (1) NA (1)	2/419 (0.48)
Total				1601		No. of FD patients: 13 Classic type, <i>n</i> (%): 5 (38.5) Late-onset type, <i>n</i> (%): 6 (46.2) Functional variants, <i>n</i> (%): 2 (15.3)	11/1598 (0.69)

NA, not applicable.